论文部分内容阅读
【目的】探讨参芎葡萄糖注射液联合胰激肽原酶肠溶片治疗早期糖尿病肾病的临床疗效。【方法】将2013年1月至2014年12月于中国医科大学附属第四医院肾内科住院治疗的72例糖尿病肾脏病患者随机分为对照组和治疗组,每组36例,其中对照组采用常规治疗方法和参芎葡萄糖注射液,治疗组在对照组基础上加用胰激肽原酶肠溶片治疗,3个月后,评价两组的血清肌酐(SCr)、尿素氮(BUN)、尿白蛋白排泄率(UAER)等改变情况及进行两组临床疗效的比较。【结果】两组治疗后 UAER 较治疗前明显下降,且差异性有显著性(P <0.05)；治疗组与对照组相比改善更为明显,且两组相比较差异性有显著性(P 0.05)。治疗组总有效率为94.4%,明显高于对照组(83.3%),且两组比较差异有显著性(P <0.05)。【结论】参芎葡萄糖注射液联合胰激肽原酶肠溶片可减少糖尿病肾脏疾病患者的尿白蛋白排出,减轻肾损害,保护肾功能,延缓病变进展。“,”[Objective]To explore the clinical efficacies of Shen-xiong injection plus kallidinogenase on proteinu-ria in patients with early diabetic nephropathy.[Methods]An exploratory study was performed for 72 diabetic ne-phropathy (DN)patients at our hospital between January 2013 and December 2014.They were randomly divided into two groups.Two groups received conventional therapy.The control group had Shen-xiong injection while the treat-ment group received both kallidinogenase and Shen-xiong injection.And the serum levels werecreatinine,blood urea nitrogen and urinary protein excretion were compared after treatment.[Results]After treatment,urinary protein ex-cretion was significantly lower than that pre-treatment and the difference was statistically significant (P <0.05).U-rinary protein excretion in treatment group was significantly lower than that in control group (P <0.05).[Conclu-sion]The combined use of Shen-xiong injection plus kallidinogenase can reduce urinary protein and protect renal func-tion during early diabetic nephropathy.